Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about COGNITIVE DECLINE: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet. View on Wiki →
No AI portrait yet
| Name | COGNITIVE DECLINE |
| Key Genes/Proteins | AMYLOID, AMYLOID-BETA, APOE4, APP, BDNF |
| Related Diseases | AGING, ALZHEIMER'S DISEASE, AUTOPHAGY |
Knowledge base pages for this entity
graph TD
COGNITIVE_DECLINE["COGNITIVE DECLINE"]
style COGNITIVE_DECLINE fill:#1a237e,stroke:#4fc3f7,stroke-width:3px
Parkinson_s_Disease["Parkinson's Disease"] -->|"causes"| COGNITIVE_DECLINE
Lecanemab{"Lecanemab"} -->|"treats"| COGNITIVE_DECLINE
Donanemab{"Donanemab"} -->|"treats"| COGNITIVE_DECLINE
Alzheimer_s_Disease["Alzheimer's Disease"] -->|"causes"| COGNITIVE_DECLINE
Postoperative_Cognitive_Dysfun["Postoperative Cognitive Dysfunction"] -->|"causes"| COGNITIVE_DECLINE
Type_2_Diabetes_Mellitus["Type 2 Diabetes Mellitus"] -->|"causes"| COGNITIVE_DECLINE
Cognitive_Resilience(Cognitive Resilience) -.->|"protects against"| COGNITIVE_DECLINE
LRP1_targeted_Polymersomes["LRP1-targeted Polymersomes"] -.->|"protects against"| COGNITIVE_DECLINE
APOE4([APOE4]) -->|"risk_factor_for"| COGNITIVE_DECLINE
Tau_Pathology["Tau Pathology"] -->|"causes"| COGNITIVE_DECLINE| Target | Relation | Type | Str |
|---|---|---|---|
| Alzheimer'S Disease | associated_with | disease | 0.95 |
| Alzheimer's Disease | associated_with | disease | 0.95 |
| Alzheimer's Disease | associated_with | disease | 0.95 |
| Alzheimer's Disease | biomarker_for | disease | 0.90 |
| ADUCANUMAB | interacts_with | drug | 0.70 |
| TAU | regulates | protein | 0.70 |
| STROKE | treats | disease | 0.70 |
| NEUROGENESIS | increases_risk | phenotype | 0.70 |
| STROKE | stabilizes | disease | 0.70 |
| STROKE | activates | disease | 0.70 |
| STROKE | protects_against | disease | 0.70 |
| STROKE | inhibits | disease | 0.70 |
| NEURODEGENERATION | stabilizes | phenotype | 0.70 |
| METFORMIN | activates | drug | 0.65 |
| NEUROGENESIS | activates | phenotype | 0.65 |
| ALZHEIMER'S DISEASE | increases_risk | disease | 0.65 |
| AMYLOID PET | regulates | biomarker | 0.65 |
| NLRP3 INFLAMMASOME | regulates | pathway | 0.65 |
| NEURODEGENERATION | treats | disease | 0.65 |
| TAU | activates | protein | 0.65 |
| NLRP3 | inhibits | gene | 0.65 |
| SYNAPTIC PLASTICITY | activates | phenotype | 0.65 |
| NEURODEGENERATION | regulates | disease | 0.65 |
| NEURONS | exacerbates | cell_type | 0.65 |
| NECROPTOSIS | inhibits | phenotype | 0.65 |
| SYNAPTIC PLASTICITY | regulates | phenotype | 0.65 |
| STROKE | interacts_with | disease | 0.65 |
| NLRP3 | activates | gene | 0.65 |
| AMYLOID | exacerbates | protein | 0.65 |
| SYNAPTIC PLASTICITY | treats | phenotype | 0.65 |
| CREB | targets | gene | 0.65 |
| NEURODEGENERATION | biomarker_for | disease | 0.60 |
| CSF | inhibits | phenotype | 0.60 |
| CSF | stabilizes | phenotype | 0.60 |
| ALZHEIMER'S DISEASE | expressed_in | disease | 0.55 |
| ALZHEIMER'S DISEASE | implicated_in | disease | 0.55 |
| FRONTAL | inhibits | concept | 0.50 |
| CA3 | associated_with | brain_region | 0.50 |
| GLUCOSE METABOLISM | interacts_with | concept | 0.50 |
| CA1 | associated_with | brain_region | 0.50 |
| DEFERIPRONE | associated_with | drug | 0.50 |
| NEUROFIBRILLARY TANGLES | associated_with | concept | 0.50 |
| FURIN | associated_with | concept | 0.50 |
| WHITE MATTER | associated_with | brain_region | 0.50 |
| ADUCANUMAB | associated_with | drug | 0.50 |
| MMSE | associated_with | biomarker | 0.50 |
| VISUAL CORTEX | associated_with | brain_region | 0.50 |
| HYPOTHALAMUS | associated_with | brain_region | 0.50 |
| DASATINIB | associated_with | drug | 0.50 |
| QUERCETIN | associated_with | drug | 0.50 |
| Source | Relation | Type | Str |
|---|---|---|---|
| APOE4 | predicts | gene | 1.00 |
| FTO | inhibits | gene | 0.95 |
| Postoperative Cognitive Dysfunction | causes | disease | 0.95 |
| Lecanemab | treats | drug | 0.95 |
| Donanemab | treats | drug | 0.95 |
| Alzheimer's Disease | causes | disease | 0.95 |
| ALZHEIMER'S DISEASE | causes | disease | 0.95 |
| Obesity | causes | disease | 0.95 |
| Parkinson's Disease | causes | disease | 0.95 |
| APOE | associated_with | gene | 0.95 |
| Alzheimer'S Disease | causes | disease | 0.95 |
| T2DM | associated_with | disease | 0.95 |
| P-Tau+/Bd-Tau+ Profile | risk_factor_for | biomarker | 0.93 |
| Bd-Tau | biomarker_for | biomarker | 0.93 |
| LRP1-targeted Polymersomes | protects_against | compound | 0.92 |
| Cognitive Resilience | protects_against | phenotype | 0.92 |
| Type 2 Diabetes Mellitus | causes | disease | 0.92 |
| Alps Index | associated_with | biomarker | 0.90 |
| APOE-ε4 | associated_with | gene | 0.90 |
| Ginsenoside Compound K | associated_with | compound | 0.90 |
| tau neurofibrillary tangles | causes | entity | 0.90 |
| Histone Deacetylation | causes | process | 0.90 |
| ageing | promotes | process | 0.90 |
| HMGB1 | causes | protein | 0.90 |
| APOE | associated_with | entity | 0.90 |
| Amyloid-beta | causes | protein | 0.90 |
| Blood-Brain Barrier | causes | entity | 0.90 |
| APOE ε4 | causes | gene | 0.90 |
| neuronal loss | causes | phenotype | 0.90 |
| ERK | prevents | protein | 0.90 |
| Neurodegeneration | causes | process | 0.90 |
| Parkinson'S Disease | causes | disease | 0.90 |
| Chronic Inflammation | contributes_to | mechanism | 0.90 |
| Defective Insulin Signaling | causes | process | 0.90 |
| Physical Exercise | protects_against | process | 0.90 |
| Ageing | causes | process | 0.90 |
| anti-amyloid immunotherapy | slows | therapy | 0.90 |
| Synapse Loss | associated_with | phenotype | 0.90 |
| Bioenergetics | drives | pathway | 0.90 |
| TNF-α/NF-κB/NLRP3 | causes | pathway | 0.90 |
| High-Fat Diet | causes | process | 0.90 |
| vascular aging | contributes_to | process | 0.90 |
| Tau Protein Hyperphosphorylation | causes | mechanism | 0.90 |
| APOE4 | risk_factor_for | protein | 0.90 |
| Tau Pathology | causes | process | 0.90 |
| Amyloid Beta | contributes_to | protein | 0.90 |
| Parkinson Disease | associated_with | disease | 0.90 |
| Neurodegeneration | contributes_to | process | 0.90 |
| Amyloid-Beta PET Burden | mediates | biomarker | 0.88 |
| Radiation-Induced Brain Injury | causes | disease | 0.88 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| No targeting hypotheses | |||
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.739
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| No papers found | ||||
Multi-agent debates referencing this entity